ScripEli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn
ScripEnliven Therapeutics believes its candidate ELVN-001 could become a second-line therapy in chronic myeloid leukemia (CML) and eventually challenge Novartis’s Scemblix in first-line use, and has just r
In VivoWhen Thijs Spoor was weighing his next career move in 2022, one option stood out despite its humble appearance. While other opportunities offered larger funding rounds and flashier platforms, a small
ScripUCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d